Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study

JIAN-RI LI, SHIAN-SHIANG WANG, KEVIN LU, CHAUN-SHU CHEN, CHEN-LI CHENG, SHENG-CHUN HUNG, KUN-YUAN CHIU, CHIANN YI HSU and CHENG-KUANG YANG
Anticancer Research March 2023, 43 (3) 1331-1339; DOI: https://doi.org/10.21873/anticanres.16281
JIAN-RI LI
1Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.;
2Division of Surgical Intensive Care Unit, Department of Intensive Care, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.;
3Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C.;
4Department of Medicine and Nursing, Hungkuang University, Taichung, Taiwan, R.O.C.;
5Institute of Biomedical Science, National Chung Hsing University, Taichung, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHIAN-SHIANG WANG
1Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.;
3Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C.;
6Department of Applied Chemistry, National Chi Nan University, Nantou, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEVIN LU
1Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHAUN-SHU CHEN
1Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.;
3Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHEN-LI CHENG
1Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.;
3Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHENG-CHUN HUNG
1Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.;
3Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KUN-YUAN CHIU
1Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.;
6Department of Applied Chemistry, National Chi Nan University, Nantou, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHIANN YI HSU
7Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHENG-KUANG YANG
1Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gu5121@vghtc.gov.tw
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 43 (3)
Anticancer Research
Vol. 43, Issue 3
March 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study
JIAN-RI LI, SHIAN-SHIANG WANG, KEVIN LU, CHAUN-SHU CHEN, CHEN-LI CHENG, SHENG-CHUN HUNG, KUN-YUAN CHIU, CHIANN YI HSU, CHENG-KUANG YANG
Anticancer Research Mar 2023, 43 (3) 1331-1339; DOI: 10.21873/anticanres.16281

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study
JIAN-RI LI, SHIAN-SHIANG WANG, KEVIN LU, CHAUN-SHU CHEN, CHEN-LI CHENG, SHENG-CHUN HUNG, KUN-YUAN CHIU, CHIANN YI HSU, CHENG-KUANG YANG
Anticancer Research Mar 2023, 43 (3) 1331-1339; DOI: 10.21873/anticanres.16281
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Role of 1p/19q Codeletion in Diffuse Low-grade Glioma Tumour Prognosis
  • Identification of Patients With Glioblastoma Who May Benefit from Hypofractionated Radiotherapy
  • Optimal Treatment of Hormone Receptor-positive Advanced Breast Cancer Patients With Palbociclib
Show more Clinical Studies

Similar Articles

Keywords

  • Immune check point inhibitors
  • Urothelial carcinoma
  • cisplatin
  • pembrolizumab
  • Atezolizumab
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire